Cross-Border Impact Ventures Announces US$58 Million First Close of Women’s and Children’s Health Technology Fund II

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions Saved Articles My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Cross-Border Impact Ventures Announces US$58 Million First Close of Women's and Children's Health Technology Fund IIAuthor of the article: You can save this article by registering for free here. Or sign-in if you have an account.Second fund builds on successful portfolio, strategic exit, and measurable global health impact as institutional investors double down on women’s and children’s health innovationTHIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountTORONTO — Cross-Border Impact Ventures (CBIV) today announced the first close of its second fund, the Women’s and Children’s Health Technology Fund II, securing US$58 million toward a target fund size of US$125 million. The new fund has attracted commitments from both returning and new institutional investors, reflecting continued confidence in CBIV’s investment strategy, team, and track record. LPs in the new fund include returning investors who doubled down, including KfW on behalf of German Federal Ministry for Economic Cooperation and Development (BMZ), the Skoll Foundation with its OCIO – Capricorn Investment Group, Ceniarth, Equality Fund with its OCIO – RockCreek Group, Wire Group, and several family offices and high-net-worth individuals, among others. CBIV expects to complete the final close of Fund II in 2027.CBIV invests in companies developing technologies that address conditions affecting women and children specifically, differently or disproportionately at the Series A or B stage. CBIV’s inaugural US$90.3 million Fund I invested in 11 technology companies spanning maternal and fetal health, neonatal care, cardiovascular disease, oncology, respiratory health, reproductive health and gut health. Fund I had a successful strategic exit and helped the portfolio reach more than 356,000 women and children across 32 countries.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againFund II represents a disciplined evolution of CBIV’s original investment thesis while maintaining its focus on early-growth-stage deep tech companies commercializing medical devices, diagnostics, therapeutics, and AI-enabled digital health technologies with the potential to generate strong financial returns alongside measurable health outcomes. CBIV has also introduced an integrated climate lens into its investment process for Fund II, has further strengthened its impact approach, and may invest earlier in some high-potential companies.Investing at the Intersection of Innovation, Returns, and Impact Fund II comes as women’s and children’s health emerges as one of healthcare’s most significant investment opportunities. CBIV estimates that its sectors of interest represent a US$625 billion market today, projected to grow to US$1.1 trillion by 2035, driven by advances in AI, diagnostics, medical devices and precision medicine, alongside growing recognition that addressing longstanding gaps in women’s and children’s healthcare represents both a societal imperative and a significant commercial opportunity.About Cross-Border Impact Ventures Cross-Border Impact Ventures (CBIV) is an impact venture capital firm on a mission to revolutionize venture investing in health technology. CBIV invests in early-growth-stage health technology companies commercializing medical devices, diagnostic tools, therapeutics, and digital health solutions. Its investment strategy focuses on companies that use advanced technologies such as Artificial Intelligence (AI) and Machine Learning (ML) to improve outcomes for health conditions that specifically, disproportionately, or differently impact women and children. The firm is driven by the belief that good health should not be restricted by gender, age, race, wealth, or borders and seeks to expand access to the world-class technologies offered by its portfolio companies, inclusively and globally. For additional information, visitView source version on businesswire.com: Boulevard Public RelationsThis advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.